- Original Articles
- Published:
Mechanisms of Tumor-Induced Immunosuppression: Evidence for Contact-Dependent T Cell Suppression by Monocytes
Molecular Medicine volume 2, pages 692–701 (1996)
Abstract
Background
The progressive growth of tumors in mice is accompanied by down-regulation of specific T cell responses. The factors involved in this suppression are not completely understood. Here, we have developed a model to examine the role of host immune effector cells in the inhibition of T cell function. In this model, progressive growth of a colon carcinoma line, CT26, is accompanied by loss of T cell response to alloantigens in both cytolytic and proliferation assays.
Materials and Methods
The CT26 tumor was inoculated into BALB/c syngeneic mice. Tumor growth, cytolytic T cell responses, lymphocyte proliferation, and flow cytometric analysis was performed in tumor-bearing animals 7 or 28 days after tumor inoculation.
Results
Spleen cells from tumor-bearing mice were found to suppress the proliferative response of spleen cells from normal mice to alloantigens. Examination of the spleen cell population by FACS analysis revealed an increase in the percentage of monocytes as defined by expression of CD1 1b, the Mac-1 antigen. Removal of the Mac-1-positive cells from the tumor-bearing hosts spleen relieved suppression of the tumor-bearing mouse spleen cell proliferative response to alloantigens, and addition of the Mac-1-positive enriched cells suppressed proliferation of normal T cells in response to alloantigens. Cell contact was required for this inhibition.
Conclusions
Tumor induction of suppressive monocytes plays an important role in the general immunosuppression noted in animals bearing CT26 tumors. Identification of the mechanisms responsible for this effect and reversal of tumor-induced macrophage suppression may facilitate efforts to develop effective immunotherapy for malignancy.
Introduction
Large tumor burden is associated with suppression of the host’s immune response to foreign antigens in both humans and animals (1,2). Defects that occur in the specific immune response include both decreased proliferation and cytolytic activity (3,4). Specific immunity is a consequence of T cells, through the T cell receptor (TCR), recognizing peptide fragments of foreign antigens in the context of self-major histocompatibility molecules while simultaneously receiving other costimulatory signals (5). Both major histocompatibility antigens and the costimulatory signals exist on professional antigen-presenting cells (APC). These APC include monocytic and dendritic cells. The T cell recognizes specific antigen in the context of a major histocompatibility antigen through its unique TCR. Once the TCR is engaged, signals are transduced into the cytoplasm through the CD3 complex, which is composed of six polypeptides, γε, δε, and ξ dimers (6). ξ may also consist of homodimers or heterodimers with η or FcεRIγ. ξ, η, CD3ε, and FcεRI all have the ability to transduce signals independently into the cytoplasm (7). It is currently unclear as to the individual role of each of these polypeptides in signal transduction and T cell activation.
Suppression of T cell responses to activation signals is also not completely understood. In murine tumor models, where suppression has been documented, studies suggest that suppressor T cells, suppressor macrophages, or suppressive cytokines secreted by tumor cells induce the impaired immune response in T cells (4,8–10). Studies evaluating the suppressive effects of monocytic cells on T cells have suggested that either adherent macrophages (10–13) or monocytes (14,15) contribute to the decreased T cell response to activation signals and also decreased the expression of the ξ chain, a major signaling protein in the TCR-CD3 complex; however, the role of soluble factors versus cell-associated gene products in mediating these effects is unclear. Studies demonstrate that while many soluble factors from monocytic cells contribute to the down-regulation of T cell responses to alloantigens (10), a contact-dependent signal is required to decrease the expression of the ξ chain (15). The effects of contact-dependent signals delivered by monocytes to T cells on allogeneic responses is unknown.
We have investigated the mechanism of T cell suppression to alloantigens in a murine model of large tumor burden. In this model, cells of the monocytic lineage, as defined by expression of CD 11b/Mac-1, gradually increase in number in the spleens of the mice as tumor size increases. In this paper, we describe the effects of these monocytes obtained by negative selection on T cells from both tumor-bearing and normal mice.
Materials and Methods
Mice
C57B1/6J (H-2b) and BALB/c (H-2d) mice were used at 6 to 10 weeks of age and were obtained from Jackson Laboratories (Bar Harbor, ME, U.S.A.). Tumor-bearing mice (TBM) were injected subcutaneously with 8 × 105 cells of a single cell suspension of CT26, a syngeneic mouse colon adenocarcinoma that had been passed subcutaneously in BALB/c mice. Single cell suspensions of tumor were prepared by mixing minced tumor in Hanks’ balanced salt solution (Sigma Chemical Co., St. Louis, MO, U.S.A.) with filtered DNAase (0.025 mg/ml, Sigma), hyaluronidase (0.025 mg/ml, Sigma) and collagenase (0.025 mg/ml, Sigma) with a stir bar for 1.5 hr at room temperature. Cells were then passed through Nytex and washed three times in Hanks’ balanced salt solution.
Cytolytic T Cell Assay
Spleen cells from TBM or naive mice were incubated for 5 days with irradiated allogeneic spleen cells (H-2b) or S194 (H-2d). On Day 5, the lymphocytes were incubated in a cytolytic assay with radiolabeled (51Cr) EL4 or YAC (MHC class I−) cells for 4 hr at 37°C as described (16). Specific lysis is defined as [(experimental — spontaneous cpm) / (total — spontaneous cpm)] × 100.
Proliferation Assay
Spleen cells from TBM and/or normal mice were incubated for the indicated number of days with irradiated allogeneic spleen cells and irradiated syngeneic spleen cells or no cells, as controls, at the indicated ratios in 96 well dishes. On Day 4, the cells were pulsed with [3H]thymidine for 16 hr and cells were harvested on a Wallac Tomtec plate harvester and incorporation measured on a Wallac β counter. Proliferation assays with membrane separations were performed in 6-well plates with cell separation across Costar’s Transwell cell culture chamber inserts with 0.4 µM pores. On Day 4, spleen cells were placed into 96-well dishes at the appropriate numbers and incorporation of [3H]thymidine measured. All assays were performed in RPMI 1640 media (Gibco, Gaithersburg, MD, U.S.A.) with 7.5% fetal calf serum, 2 mM glutamine, 5 × 10−5 M β-2-mercaptoethanol, and penicillin/streptomycin and incubated at 37°C at 5% CO2.
Flow Cytometric Analyses
Spleen cells from TBM and normal mice were blocked with an anti-Fc antibody and then stained with mAbs of appropriate specificities and analyzed on a FACScan flow cytometer (Becton Dickinson Immunocytometry systems, Mountain View, CA, U.S.A.) after gating out dead cells in Fl2 by using propidium iodide staining. The following monoclonal antibodies (mAbs) were used: rat anti-mouse CD32/16 (2.4G2), FITC-labeled rat anti-mouse CD90/Thy-1.2 (53-2.1), FITC-labeled rat anti-mouse CD45R/B220 (RA3-6B2), FITC-labeled rat anti-mouse CD11b/Mac-1 (M1/70), FITC-labeled rat IgG2b,κ, and FITC-labeled rat IgG2a,κ. All antibodies were obtained from Pharmingen (San Diego, CA, U.S.A.) and used at a concentration of 1 µg/million cells. For Fas and FasL immunostaining of T and monocytic cells, the following antibodies were used: Fas, hamster anti-mouse Fas (clone VC8-4B3) with FITC-labeled mouse anti-hamster IgG (clones G70-204 and G94-56) (Pharmingen); FasL, mouse Fas-human γ1 Fc fusion protein with FITC-labeled goat anti-human IgG Fc (Jackson Immunoresearch Lab, West Grove, PA, U.S.A.); Mac-1 (CD11b), phycoerythrin (PE-labeled rat anti-mouse CD17b (clone M1/70.15) (Caltag, Burlingame, CA, U.S.A.); Thy-1, PE-labeled rat anti-mouse CD90 (Caltag); and control, PE-labeled rat IgG2b (Caltag).
Cell Depletion
Spleen cells from TBM were depleted of T cells, B cells, and monocytes by pretreatment with rat antibody specific for the surface antigens and then removed with the use of magnetic beads coated with sheep anti-rat IgG. The following primary mAbs were used: rat anti-mouse CD90/Thy-1.2 (53-2.1), rat anti-mouse CD45R/B220 (RA3-6B2), rat anti-mouse CD11b/Mac-1 (M1/70), all rat IgG2a,κ. All antibodies were obtained from Pharmingen. Coated cells were then washed twice and incubated with Dynabeads M-450 sheep anti-rat IgG (Dynal, Oslo, Norway) at a bead-to-cell ratio of 40:1 at 4°C for 30 min on a rocker. Magnetic beads attached to cells were then removed from unattached cells with a Dynal MPC-6 magnet. Unattached cells were washed once, counted, and added to assays at appropriate ratios. Depletions were >98% for all cell types as measured by flow cytometric analyses.
Results
Inhibition of T Cell Cytotoxic and Proliferative Responses in Spleens from Late Tumor-Bearing Mice in Vitro
To evaluate T cell function in mice at early and late time periods after bearing tumors, cytolytic T cell assays were performed after appropriate in vitro sensitization. Allogeneic and NK responses were determined by a chromium release assay using either an allogeneic tumor cell line, EL4, or a class I-deficient cell line, YAK, as targets. In four separate experiments, lysis of both class I+ and class I− targets was substantially reduced when T cells were derived from the spleen of late TBM, in contrast to normal controls (Fig. 1A and B, right panel). In contrast, lysis of both class I+ and class I− targets was comparable to normal controls when cells were derived from early TBM (Fig. 1A and B, left panel), and these results were confirmed in at least two separate experiments.
In addition to its decreased cytolytic activity, the yield of cells from the late tumor-bearing mouse spleen was reduced compared with normal mouse spleen after in vitro sensitization. This finding suggested a decreased ability of the spleen cells from late TBM to proliferate in response to allogeneic stimulation. To test this hypothesis, proliferation was measured after stimulation with irradiated allogeneic spleen cells. Under conditions that allowed significant proliferation of normal mouse lymphocytes, minimal proliferation was detected in late TBM lymphocytes (Fig. 1C). Similar effects were observed at all time points (Days 3–6) at different responder-to-stimulator cell ratios (data not shown).
Spleens from Tumor-Bearing Mice Have a Higher Percentage of Monocytes, as Defined by the CD11b/Mac-1 Antigen, than Spleens from Normal Mice
To define the cell types that mediated the change in T cell responses, spleen cell suspensions from normal and late tumor-bearing mice were analyzed by flow cytometry with antibodies to mouse CD90/Thy-1.2, CD45R/B220, and CD11b/Mac-1 (Fig. 2). In late tumor-bearing mice, the percentage of CD90/Thy-1.2-positive spleen cells changed slightly from 31 to 27% of total cells, and the percentage of CD45R/B220-positive spleen cells decreased from 41 to 30%. In contrast, the percentage of CD11b/Mac-1-positive spleen cells increased from 2 to 15%. Although some subsets of cytolytic T cells express CD11b, it is unlikely that this subset represented splenic T cells, because the population of expanded CD11b+ cells showed a larger size as measured by forward light scatter than the subsets staining with Thy-1.2 antibody. In addition, cells that expressed the Mac-1 antigen also coexpressed small amounts of Mac-2 antigen, another marker of cells of monocytic lineage (data not shown). The minor shift in the T cell population suggested that the change in responsiveness of T cells was qualitative rather than quantitative. This small decrease in percentage would be unlikely to account for the large decrease in proliferation when stimulated. However, the larger shifts in the B cell and monocyte populations suggested that tumor growth was influencing their growth and survival to a greater extent in vivo.
Spleen Cells from Tumor-Bearing Mice Can Suppress Proliferation of Lymphocytes from Normal Mice
The change in phenotype of splenic cell populations in the tumor-bearing spleens suggested that the tumor may not act directly on T lymphocytes but may instead exert its effect through another immune effector cell to inhibit T cell function. To explore this possibility, mixture experiments were performed. Different ratios of normal spleen cells and TBM spleen cells were used in a standard proliferation assay, and results were compared with the proliferation of an equivalent number of normal mouse spleen cells. As the number of cells from a tumor-bearing mouse increased, there was a reciprocal decrease in proliferation by cells from a normal mouse. Also, the addition of a small proportion (10–30%) of TBM spleen cells markedly inhibited proliferation of normal cells (Fig. 3). This finding suggested there was a cell population in tumor-bearing spleens that could act in trans to inhibit the proliferation of T cells in response to allogeneic stimulation.
Depletion of CD11b+ Cells from Tumor-Bearing Mouse Spleen Restores Proliferation of the Lymphocytes in Response to Alloantigens
To identify the specific cell type responsible for the decreased allogeneic response, cell depletion experiments were performed. Different cell populations were removed from tumor-bearing mouse spleen by coating the cells with specific antibodies to either CD90/Thy-1.2, CD45R/B220, or CD11b/Mac-1 antigen, and these cells were removed with the use of magnetic beads coated with anti-immunoglobulin. The remaining cells were analyzed by using a standard allogeneic proliferation assay. Depletion of CD11b/Mac-1-positive cells restored the ability of TBM spleen cell to proliferate in response to an allogeneic stimulus (Fig. 4A). In contrast, depletion of CD45R/B220 cells, largely composed of B cells, resulted in a small loss of suppression and was much less effective than removal of CD11b/Mac-1 cells (Fig. 4A). As expected, no proliferation was observed after CD90/Thy-1.2-positive cell depletion or with a nonspecific control antibody (Fig. 4A). Although T cells demonstrated increased proliferation to allogeneic stimuli when the monocytes were removed, proliferation did not increase to levels of control normal mouse spleen cells.
To determine whether the T cell could act in trans on normal T cells, mixing experiments were performed with tumor-bearing spleen cells depleted or enriched for T cells (Fig. 4B). CD90/Thy-1.2-depleted TBM spleen cells inhibited normal mouse spleen cells at a 9:1 ratio to the same extent as TBM cells without depletions (Fig. 4B). Enrichment of T cells by CD45R/B220 and CD11b/Mac-1 depletion demonstrated a greater proliferative response than nondepleted cells (Fig. 4B). Therefore, it appeared that the CD11b/Mac-1 cell from TBM was responsible for the major inhibitory signals to T cells.
Cell Contact Is Required for Inhibition of Naive Spleen Cell Responses to Alloantigens by the CD90/Thy-1.2−, CD45R/B220− Cell Population from Tumor-Bearing Mouse Spleen
To determine whether cell contact or soluble factors mediated this effect, inhibition by the CD11b/Mac-1 cell was analyzed further by supernatant transfer and membrane separation experiments. Transfer of supernatant from CD90/Thy-1.2 and CD45R/B220 depleted TBM spleen failed to confer suppression upon normal spleen cells (Fig. 5A). Also, the addition of neutralizing antibodies to mouse transforming growth fac-tor-β (TGF-β), interleukin 10 (IL-10), and tumor necrosis factor α (TNFα) or indomethacin, which inhibits PGE2 production, to proliferation assays using TBM spleen did not change T cell proliferation (data not shown). In contrast, cell contact conferred this inhibition (Fig. 5A).
To confirm these results, experiments were also performed with cells of the TBM separated from normal mouse spleen by a membrane in a proliferation assay. When the cells were separated, there was no inhibition of proliferation, but when cell contact was allowed there was significant inhibition of proliferation of the normal mouse cells (Fig. 5B). Although isolated cell membranes did not confer suppression, high concentrations of glutaraldehyde-fixed cells did mediate the effect, suggesting that intact cells and continued protein synthesis are required for optimal immunosuppression. This data suggests that either a membrane bound or a cell-associated factor mediates inhibition of the T cell in response to activation signals.
Analysis of monocytic cells derived from primary tumors was performed. Cell suspensions were prepared after digestion with collagenase and elastase, and immunofluorescence analysis was performed. The expression of Fas ligand was found to be elevated in monocytes derived from tumor cells (Fig. 6B), in contrast to monocytic cells described previously from spleen and other lymphoid organs. No significant increased expression of Fas or FasL was detected in T cells, although a small (~3-fold) increase in CD3 expression was noted in these cells (data not shown). These data raise the possibility that Fas ligand may contribute to the immunosuppression induced in tumor-bearing animals.
Discussion
We have demonstrated a quantitative increase in monocytes which inhibit T cell proliferation and cytotoxicity in mice with large burdens of a sub-cutaneously implanted tumor, CT26. Decreased immune function was observed in animals with a large tumor burden. Cytolytic and proliferative T cell responses to alloantigen and natural killer (NK) activity were markedly diminished. Increased levels of monocytic cells were detected in the spleen of these animals, and we find that this cell type was responsible for the reduction in T cell response. Finally, we have found that contact between T cells and monocytes was required for this inhibitory effect.
This study provides insight into the mechanism of tumor-induced immunosuppression. Defects in the immune response of tumor-bearing animals have been attributed to soluble factors produced by tumor cells, which act directly on T cells or indirectly, through the induction of other suppressor cells, either T cells or macrophages (4,8–10). In the animal model described in this study, it was found that the monocyte conferred suppressive activity on the T cell. Other groups who have found monocytic cells to be suppressive have shown that soluble factors, including PGE2 and TGF-β, were important in the suppression of lymphocyte proliferation (11–14). In contrast, we found that cell contact was required to inhibit T cell function. These differences could be accounted for by a difference in tumor type or, alternatively, by the methods used to obtain the monocytes. Studies that have found soluble factors to be important obtained monocytic cells by separating cells on the basis of adherence, which may induce activation and enhance cytokine secretion. These effects could mask the additional inhibitory effects of cell surface molecules. In the present study, cells were derived by enrichment through the negative selection of T and B cells. When a positive selection by Mac-1 and Mac-2 antigens or depletion of T and B cells were used to isolate monocytes, however, no evidence of soluble inhibitors of T cell function was detected (14,15), consistent with findings reported here.
There is both direct and indirect evidence to suggest that tumor induction of suppressive monocytes may represent a general mechanism of tumor-induced immunosuppression. First, several groups using different tumor lines have noted an increase in the percentage of monocytes in the spleen of late tumor-bearing animals (10,12,17). Second, several different cell lines have quantitative changes in the ζ-chain of the TCR complex, which is induced by cell contact with monocytes derived from tumor-bearing animals (15,18). Third, monocytes from animals bearing the D1-DMBA-3 mammary adenocarcinoma induces suppression of naive T cells by a contact-dependent manner in response to Con A (14).
The mechanism by which tumor cells induce a suppressive phenotype in monocytes is currently unknown. It is possible that tumor cells provide signals to these immune cells by two mechanisms. First, tumor cells have been demonstrated to elaborate a variety of cytokines, and these could induce the monocyte to become suppressive. Such a cytokine would induce the monocyte to deliver signals to the T cell which inhibit the response to activation signals. Although it is possible that such cytokines could affect antigen presentation, such a defect would not likely be responsible for the inhibition observed here, since antigen-presenting cells reside in the allogeneic irradiated stimulator population and provide costimulatory signals in our experiments. While there would be many candidate cytokines that would prevent antigen presentation to the T cell and that are produced by tumors, such as IL-10 and IL-1 receptor antagonist (19,20), no soluble factors are known that induce the monocytic phenotype noted in our studies. Alternatively, chronic stimulation of the immune system by large amounts of tumor antigens may alter TCR and cytokine signaling through immune cell surface interactions. In support of this theory, it has been shown that antibody to CD14 on human monocytes induces a contact-dependent signal to T cells, which inhibits proliferation in response to activation signals. It has been proposed that a CD14 ligand might exist on activated T cells which interacts with CD14 on monocytes as part of a negative regulatory circuit (21). Although the molecule induced on the monocyte is not known, the finding of increased FasL expression in this population suggests its potential involvement in this effect. It may also provide a useful surrogate marker for tumor-induced immunosuppression.
The molecular signal from monocyte to T cell in this study is membrane or cell associated. Candidate molecules could include TGF-β and nitric oxide, as they have been demonstrated to decrease proliferation of activated lymphocytes and can be associated with the membrane (TGF-β) (22) or lose activity quickly after being released from the cell (nitric oxide) (23). In some instances, TGF-β antibodies can reverse inhibition by monocytes, for example, in hyperimmunized mice (22), however, neither of these molecules has been demonstrated to decrease ξ expression in the TCR, and neutralizing antibodies to TGF-β did not block the negative signal to T cells in this study (data not shown). These findings suggest that TGF-β is not involved in decreasing T cell proliferation in our system.
The CD11b/Mac-1+ monocytic cell from tumor-bearing mice has been demonstrated to down-regulate T cell responses to alloantigens. This data, in conjunction with recent studies that demonstrate that CD11b/Mac-1+ cells down-regulate expression of the ξ-chain of the CD 3-TCR complex supports the hypothesis that a CD11b/Mac1+ cell-associated factor plays an important role in determining responsiveness to antigens in animals with a large tumor burden. The monocyte, which in some instances can provide appropriate peptide fragments and costimulatory molecules to activate specific T cells, could provide inhibitory signals to prevent T cell proliferation in response to appropriate activation signals. The capacity to inhibit such T cell responses may be an important control mechanism not only in tumor-induced evasion of immune responses, but also for appropriate recognition of viral proteins and auto-antigens.
References
Broder S, Waldmann TA. (1978) The suppressor network in cancer. N. Engl. J. Med. 299: 1281–1284.
Deckers PJ, Davis RC, Parker GA, Mannick JA. (1973) The effect of tumor size on concomitant tumor immunity. Cancer Res. 33: 139.
Maccubbin DL, Mace KF, Ehrke MJ, Mihich E. (1989) Modification of host antitumor defense mechanisms in mice by progressively growing tumor. Cancer Res. 49: 4216–4224.
North RJ, Bursuker I. (1984) Generation and decay of the immune response to a progressive fibrosarcoma. J. Exp. Med. 159: 1312–1321.
Janeway CA, Golstein P. (1993) Lymphocyte activation and effector functions. Curr. Opin. Immunol. 5: 313–323.
Weiss A. (1993) T cell antigen receptor signal transduction: A tale of tails and cytoplasmic protein-tyrosine kinases. Cell 73: 209–212.
Weiss A, Littman DR. (1994) Signal transduction by lymphocyte antigen receptors. Cell 76: 263–274.
Tada T, Ohzeki S, Utsumi K, et al. (1991) Transforming growth factor-β-induced inhibition of T cell function. J. Immunol. 146: 1077–1082.
Young RM, Wright MA, Coogan M, Young ME, Bagash J. (1992) Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor β. Cancer Immunol. Immunother. 35: 14–18.
Malick AP, Garner R, Black SP, Elgert KD. (1984) Normal and tumor-bearing host macrophage factor-mediated modulation of mixed-lymphocyte reaction responsiveness: Separation of T-lymphocyte subset susceptibility to enhancing and inhibitory factors. Cell. Immunol. 85: 11.
Walker TM, Burger CJ, Elgert KD. (1994) Tumor growth alters T cell and macrophage production of and responsiveness to granulocyte-macrophage colony-stimulating factor: Partial dysregulation through interleukin-10. Cell. Immunol. 154: 342–357.
Fu Y, Watson G, Jimenez JJ, Wang Y, Lopez DM. (1990) Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res. 50: 227–234.
Parhar RS, Lala PK. (1988) Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages. J. Leukoc. Biol. 44: 474–484.
Watson GA, Fu Y, Lopez DM. (1991) Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. J. Leukoc. Biol. 49: 126–138.
Aoe T, Okamoto Y, Saito T. (1995) Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J. Exp. Med. 181: 1881–1886.
Plautz GE, Yang Z, Wu B, Gao X, Huang L, Nabel GJ. (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. U.S.A. 90: 4645–4649.
Fernandez-Cruz E, Gilman SC, Feldman JD. (1982) Altered levels of mononuclear leukocytes in tumor-bearing rats: decrease of helper T lymphocytes and increase of suppressor cells. J. Immunol. 129: 1324–1328.
Mizoguchi H, O’Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795–1798.
Smith DR, Kunkel SL, Burdick MD, et al. (1994) Production of interleukin-10 by human bronchogenic carcinoma. Am. J. Pathol. 145: 18–25.
Howard M, O’Garra A. (1992) Biological properties of interleukin 10. Immunol. Today 13: 198–200.
Ko-Huang L, Lauener RP, Winchester RJ, Geha RS, Vercelli D. (1991) Engagement of CD14 on human monocytes terminates T cell proliferation by delivering a negative signal to T cells. J. Immunol. 147: 1134–1138.
Stach RM, Rowley DA. (1993) A first or dominant immunization, II Induced immunoglobulin carries transforming growth factor β and suppresses cytolytic T cell responses to unrelated alloantigens. J. Exp. Med. 178: 841–852.
Denham S, Rowland IJ. (1992) Inhibition of the reactive proliferation of lymphocytes by activated macrophages: The role of nitric oxide. Clin. Exp. Immunol. 87: 157–162.
Acknowledgments
We would like to thank Donna Gschwend for secretarial assistance, Karen Carter for preparation of figures, Judy Stein for help in figure preparation and statistical analysis, and Dr. Keith Bishop for helpful advice and discussion. This work was supported in part by a grant from the National Institutes of Health (P01 CA59327-01; NIH).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jaffe, M.L., Arai, H. & Nabel, G.J. Mechanisms of Tumor-Induced Immunosuppression: Evidence for Contact-Dependent T Cell Suppression by Monocytes. Mol Med 2, 692–701 (1996). https://doi.org/10.1007/BF03401653
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03401653